Clinical Study

Cg01-Gbm Standard Chemotherapy Versus Chemotherapy Chosen By Cancer Stem Cell Chemosensitivity Testing In The Management Of Patients With Recurrent Glioblastoma Multiforme (Gbm).

Posted Date: Jun 10, 2019

  • Investigator: Lalanthica Yogendran
  • Specialties: Cancer, Oncology
  • Type of Study: Observational/Survey

To evaluate median overall survival in recurrent glioblastoma multiforme patients who have had a ChemoID assay-guided treatment compared to standard therapy chosen by the physician


To Be Eligible You Must Be At Least 18 Years Old, Have A Recurrent Surgically Resectable Tumor, Survival Expentency Of Over 3 Months, Nonpregnant And Nonnursing.


Brain Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.